NO20044333L - Farmasoytiske kombinasjon for behandling av godartet prostatis hyperplasi eller for langtidsprevensjon av akutt urinretensjon - Google Patents

Farmasoytiske kombinasjon for behandling av godartet prostatis hyperplasi eller for langtidsprevensjon av akutt urinretensjon

Info

Publication number
NO20044333L
NO20044333L NO20044333A NO20044333A NO20044333L NO 20044333 L NO20044333 L NO 20044333L NO 20044333 A NO20044333 A NO 20044333A NO 20044333 A NO20044333 A NO 20044333A NO 20044333 L NO20044333 L NO 20044333L
Authority
NO
Norway
Prior art keywords
long
pharmaceutical combination
treatment
urinary retention
acute urinary
Prior art date
Application number
NO20044333A
Other languages
English (en)
Norwegian (no)
Inventor
Wolfgang Baiker
Ludwig Mehlburger
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29271571&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20044333(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2002118392 external-priority patent/DE10218392A1/de
Priority claimed from DE2002118611 external-priority patent/DE10218611A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20044333L publication Critical patent/NO20044333L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
NO20044333A 2002-04-24 2004-10-12 Farmasoytiske kombinasjon for behandling av godartet prostatis hyperplasi eller for langtidsprevensjon av akutt urinretensjon NO20044333L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2002118392 DE10218392A1 (de) 2002-04-24 2002-04-24 Verwendung von Arzneimittelkombinationen zur Behandlung von benigner Prostatahyperplasie
DE2002118611 DE10218611A1 (de) 2002-04-25 2002-04-25 Verwendung einer Tamsulosin enthaltenden Arzneimittelkombination zur Behandlung von benigner Prostatahyperplasie
PCT/EP2003/004034 WO2003090753A1 (en) 2002-04-24 2003-04-17 Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention

Publications (1)

Publication Number Publication Date
NO20044333L true NO20044333L (no) 2004-11-09

Family

ID=29271571

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044333A NO20044333L (no) 2002-04-24 2004-10-12 Farmasoytiske kombinasjon for behandling av godartet prostatis hyperplasi eller for langtidsprevensjon av akutt urinretensjon

Country Status (22)

Country Link
US (2) US20030225118A1 (ja)
EP (2) EP1743656A3 (ja)
JP (1) JP2005524693A (ja)
CN (1) CN1646135A (ja)
AT (1) ATE361075T1 (ja)
AU (1) AU2003227643A1 (ja)
BR (1) BR0309435A (ja)
CA (1) CA2479992A1 (ja)
CY (1) CY1107674T1 (ja)
DE (1) DE60313603T2 (ja)
DK (1) DK1501517T3 (ja)
EA (1) EA008377B1 (ja)
ES (1) ES2287474T3 (ja)
HR (1) HRP20040994A2 (ja)
IL (1) IL163976A0 (ja)
MX (1) MXPA04010408A (ja)
NO (1) NO20044333L (ja)
NZ (1) NZ536514A (ja)
PL (1) PL371430A1 (ja)
PT (1) PT1501517E (ja)
RS (1) RS92304A (ja)
WO (1) WO2003090753A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1743656A3 (en) * 2002-04-24 2007-03-07 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
KR20060124603A (ko) * 2003-11-03 2006-12-05 베링거 인겔하임 인터내셔날 게엠베하 베타-3-아드레날린 수용체 효능제 및 알파 길항제 및/또는5-알파-리덕타제 억제제를 함유하는 약제학적 조성물
CN100451797C (zh) * 2003-11-14 2009-01-14 株式会社半导体能源研究所 显示装置及其制造法
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
CN102309495A (zh) * 2010-06-30 2012-01-11 北京润德康医药技术有限公司 一种复方制剂及其制备方法
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
BRPI1103204A2 (pt) * 2011-06-03 2014-02-25 Eurofarma Lab S A Composição farmacêutica para o tratamento de hiperplasia prostática benigna
WO2013123965A1 (en) 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
BR102013020508B1 (pt) * 2013-08-12 2021-01-12 Ems S/A. Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
EP2949319A1 (en) 2014-05-26 2015-12-02 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
WO2017058436A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
US10172910B2 (en) * 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
CN115969860A (zh) * 2021-10-14 2023-04-18 上海汇伦医药股份有限公司 一种药物组合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US4760071A (en) 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
NZ211145A (en) 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
EP0285382B1 (en) 1987-04-03 1994-04-13 Merck & Co. Inc. Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
DE3888378T2 (de) 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW382595B (en) 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US6423719B1 (en) * 1999-02-16 2002-07-23 Upsher-Smith Laboratories, Inc. Method for treating benign prostate hyperplasia
AU7703700A (en) * 1999-09-22 2001-04-24 Merck & Co., Inc. Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein
EP1743656A3 (en) * 2002-04-24 2007-03-07 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention

Also Published As

Publication number Publication date
RS92304A (en) 2006-10-27
EP1743656A2 (en) 2007-01-17
ES2287474T3 (es) 2007-12-16
HRP20040994A2 (en) 2005-02-28
BR0309435A (pt) 2005-02-15
EA200401340A1 (ru) 2005-06-30
CN1646135A (zh) 2005-07-27
NZ536514A (en) 2006-11-30
PL371430A1 (en) 2005-06-13
DE60313603D1 (de) 2007-06-14
EP1501517A1 (en) 2005-02-02
ATE361075T1 (de) 2007-05-15
CA2479992A1 (en) 2003-11-06
IL163976A0 (en) 2005-12-18
EP1501517B1 (en) 2007-05-02
WO2003090753A1 (en) 2003-11-06
US20070197666A1 (en) 2007-08-23
CY1107674T1 (el) 2013-04-18
MXPA04010408A (es) 2005-02-17
WO2003090753A8 (en) 2004-11-04
US20030225118A1 (en) 2003-12-04
PT1501517E (pt) 2007-05-31
AU2003227643A1 (en) 2003-11-10
DK1501517T3 (da) 2007-06-11
EA008377B1 (ru) 2007-04-27
EP1743656A3 (en) 2007-03-07
DE60313603T2 (de) 2008-01-03
JP2005524693A (ja) 2005-08-18

Similar Documents

Publication Publication Date Title
CY1107674T1 (el) Φαρμακευτικος συνδυασμος για τη θεραπευτικη αντιμετωπιση της καλοηθους υπερπλασιας του προστατη ή για την μακροπροθεσμη προληψη της οξειας επισχεσης ουρων
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
DE60045751D1 (de) Therapeutische Behandlung androgenrezeptorbedingter Leiden
DK0968208T3 (da) Quinolin- og quinazolin-forbindelser som er nyttige i terapi især til behandling af godartet prostatisk hyperplasia
IL169685A0 (en) Treatment of benign prostatic hyperplasia using energolytic agents
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
HUP0100586A2 (hu) Alsó húgyvezetéki tünetek kezelésére alkalmas gyógyászati készítmények
BR9812122A (pt) Combinação de inibidor da tirosina quinase e castração quìmica para tratar câncer da próstata
BR0013219A (pt) Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
EA200301104A1 (ru) Антиангиогенная комбинированная терапия для лечения онкологических заболеваний
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
HUP0104688A2 (hu) Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
DK1368054T3 (da) Anvendelse af neurale trådproteiner til behandling af tumorer
DK0565296T3 (da) Anvendelse af melatonin til fremstilling af et lægemiddel til behandling af godartet prostatahyperplasi
ATE250580T1 (de) Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie
EA200401100A1 (ru) 1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ
WO2007141661A3 (en) Herbal compositions for the prevention or treatment of benign prostatic hyperplasia
DK1345907T3 (da) 7-Heterocyclyl-quinolin- og thieno-2,3-B-pyridin-derivater anvendelige som antagonister af gonadotropin-frigörende hormon
NO975838L (no) Melatoninagonister for behandling av godartet prostatisk hyperplasi
EP1485117A4 (en) METHOD FOR THERAPEUTIC TREATMENT OF BENIGN PROSTATE HYPERTROPHY (BPH)
ATE222263T1 (de) Prostata-spezifische antigen inhibitore
EP1435913A4 (en) METHOD OF TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER BENCH PROSTATIC PATHOLOGIES
UA3401U (uk) Спосіб хірургічного лікування гострої затримки сечі у хворих на доброякісну гіперплазію передміхурової залози, ускладнену уретерогідронефрозом
WO2002077162A3 (en) Gene (t23490) associated with benign prostatic hyperplasia
GB9810895D0 (en) Combination therapy for the treatment of benign prostatic hyperplasia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application